HomeCompareSAGE vs PG

SAGE vs PG: Dividend Comparison 2026

SAGE yields 23.04% · PG yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SAGE wins by $36.4K in total portfolio value
10 years
SAGE
SAGE
● Live price
23.04%
Share price
$8.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$87.8K
Annual income
$9,210.28
Full SAGE calculator →
PG
Procter & Gamble
● Live price
2.92%
Share price
$144.73
Annual div
$4.23
5Y div CAGR
31.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.4K
Annual income
$9,955.44
Full PG calculator →

Portfolio growth — SAGE vs PG

📍 SAGE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAGEPG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAGE + PG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAGE pays
PG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAGE
Annual income on $10K today (after 15% tax)
$1,958.53/yr
After 10yr DRIP, annual income (after tax)
$7,828.74/yr
PG
Annual income on $10K today (after 15% tax)
$248.27/yr
After 10yr DRIP, annual income (after tax)
$8,462.12/yr
At 15% tax rate, PG beats the other by $633.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAGE + PG for your $10,000?

SAGE: 50%PG: 50%
100% PG50/50100% SAGE
Portfolio after 10yr
$69.6K
Annual income
$9,582.86/yr
Blended yield
13.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PG right now

SAGE
Analyst Ratings
7
Buy
27
Hold
2
Sell
Consensus: Hold
Price Target
$37.33
+330.1% upside vs current
Range: $5.00 — $105.00
Altman Z
-5.3
Piotroski
3/9
PG
Analyst Ratings
29
Buy
22
Hold
1
Sell
Consensus: Buy
Price Target
$167.67
+15.9% upside vs current
Range: $150.00 — $179.00
Altman Z
5.3
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAGE buys
0
PG buys
0
No recent congressional trades found for SAGE or PG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAGEPG
Forward yield23.04%2.92%
Annual dividend / share$2.00$4.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%31.1%
Portfolio after 10y$87.8K$51.4K
Annual income after 10y$9,210.28$9,955.44
Total dividends collected$53.6K$29.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$37.33$167.67

Year-by-year: SAGE vs PG ($10,000, DRIP)

YearSAGE PortfolioSAGE Income/yrPG PortfolioPG Income/yrGap
1← crossover$13,004$2,304.15$11,003$382.92+$2.0KSAGE
2$16,715$2,800.32$12,205$520.11+$4.5KSAGE
3$21,249$3,363.90$13,674$712.22+$7.6KSAGE
4$26,733$3,996.60$15,507$985.02+$11.2KSAGE
5$33,303$4,699.14$17,847$1,378.96+$15.5KSAGE
6$41,105$5,471.12$20,913$1,959.19+$20.2KSAGE
7$50,294$6,311.13$25,044$2,834.00+$25.3KSAGE
8$61,031$7,216.72$30,786$4,189.46+$30.2KSAGE
9$73,488$8,184.51$39,052$6,357.54+$34.4KSAGE
10$87,842$9,210.28$51,429$9,955.44+$36.4KSAGE

SAGE vs PG: Complete Analysis 2026

SAGEStock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Full SAGE Calculator →

PGConsumer Staples

The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; and antiperspirants and deodorants, personal cleansing, and skin care products under the Olay, Old Spice, Safeguard, Secret, and SK-II brands. The Grooming segment provides shave care products and appliances under the Braun, Gillette, and Venus brand names. The Health Care segment offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brand names; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, pain relief, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. The Fabric & Home Care segment provides fabric enhancers, laundry additives, and laundry detergents under the Ariel, Downy, Gain, and Tide brands; and air care, dish care, P&G professional, and surface care products under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. The Baby, Feminine & Family Care segment offers baby wipes, taped diapers, and pants under the Luvs and Pampers brands; adult incontinence and feminine care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. The company sells its products primarily through mass merchandisers, e-commerce, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.

Full PG Calculator →
📬

Get this SAGE vs PG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAGE vs SCHDSAGE vs JEPISAGE vs OSAGE vs KOSAGE vs MAINSAGE vs KMBSAGE vs CLSAGE vs CHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.